600 patients66,869 observations120 daysLIVE

Patient P-01612

Synthetic patientNBL-101 · Day 112 · 25–34 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Unstable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 45 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 52 GI-04 recommendedGI Support Protocol GI-04
  4. Day 53 Patient declinedNot now
  5. Day 68 ME-01 recommendedMonitoring Escalation ME-01
  6. Day 69 Patient acceptedStarted ME-01 in the companion
  7. Day 72 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days
  • Toxicity+15
  • Nutritional resilience-7
  • GI instability-4

What helped?

  • GI Support Protocol GI-04Day 52
    Declined by patient
  • Monitoring Escalation ME-01Day 68
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
64.9/100
stable · -1.5 vs previous 14 d
Toxicity
Blood
61.7/100
stable · -1.9 vs previous 14 d
Sleep quality
Wearable
37.8/100
worsening · -2.8 vs previous 14 d
Energy level
Daily log
2.5/10
improving · +0.1 vs previous 14 d
Stress level
Daily log
6.3/10
stable · -0.1 vs previous 14 d
Steps
Wearable
3,953
stable · +88 vs previous 14 d
Adherence
Companion
44.5 %
stable · +0.6 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 27 from the failing basin, 69 from restoration.

Would help
  • GI-04 GI Support Protocol
    73% improved among 124 similar · onset 8 d · confidence 97%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 77%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 77%
Would not help
  • Keep fat low
    GI +5.7 next day on high-intake days · n 22
  • Keep histamine low
    GI +5.6 next day on high-intake days · n 17
  • Keep fibre low
    GI +4.7 next day on high-intake days · n 18
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +5.7detractor · 95%
  • Histamine load
    +5.6detractor · 95%
  • Insoluble fibre
    +4.7detractor · 95%
  • Simple carbohydrates
    +3.9detractor · 92%
  • Spicy / capsaicin
    +1.1no signal · 20%
  • Alcohol
    +0.5no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 65 and rising
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 23/100
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 50
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 64
  • Autonomic recovery 45
    • WearableResting HR 88 bpm
    • Wearable3,953 steps/day
  • Drug metabolism and exposure 20
    • BloodToxicity index 62
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.4 · butyrate capacity 23/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
52 ms
Sleep
6.4 h
Steps
4,708
Resting HR
87 bpm
Daily log: GI score 65, nutritional resilience 32, adherence 45.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0184164%S1448
P-0158257%S14GI-04no change45
P-0188855%S1456
P-0146354%S14NP-02no change41
P-0153154%S14ME-01improved51
P-0172854%S14SC-12improved41
P-0157253%S14GI-04worsened41
P-0174353%S14SC-12no change52
P-0139652%S14GI-04worsened51
P-0175152%S14ME-01improved48
P-0183052%S1444
P-0189752%S14ME-01improved43